Clinical Trials Browser

Phase 2/3 × veliparib × 90 days × Clear all

NCT02152982 2026-03-18

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2/3 Active not recruiting

447 enrolled 20 charts

Glioblastoma, Gliosarcoma